SCHEMBL25816524

SCHEMBL25816524

Cc1cnc([C@@H]2CC(O)ON2C(=O)OC(C)(C)C)cn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
GPR119 Q8TDV5 7/20 0.33
CYP1A2 P05177 1/20 0.32
POLB P06746 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
NR1H2 P55055 1/20 0.32
GRM5 P41594 1/20 0.31
USP30 Q70CQ3 1/20 0.31
ALDH1A1 P00352 1/20 0.31
ELANE P08246 1/20 0.31
LMNA P02545 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25816507 0.84 GPR119 (0.43) CHRM2CHRM1CHRM3GPR119USP30
SCHEMBL30338608 0.84 GPR119 (0.43) CHRM2CHRM1CHRM3GPR119USP30
SCHEMBL25816465 0.84 CHRM2 (0.33) CHRM2CHRM1CHRM3GPR119NR1H2
SCHEMBL31205643 0.83 DGAT1 (0.37) KMT2AMEN1MAPTTSHRSMN1; SMN2
SCHEMBL25816515 0.82 MEN1 (0.36) KMT2AMEN1MAPTTSHRPOLB
SCHEMBL30339011 0.82 MEN1 (0.36) KMT2AMEN1MAPTTSHRPOLB
SCHEMBL30547535 0.80 GPR119 (0.40) GPR119
SCHEMBL25816597 0.80 GPR119 (0.40) GPR119
SCHEMBL30338783 0.80 RIPK1 (0.44) GPR119POLBGRM5USP30ALDH1A1
SCHEMBL31205811 0.80 GPR119 (0.40) CHRM2CHRM1CHRM3GPR119CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 CN disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed
EP-4157835-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 KMT2A 3609/4885MEN1 4787/4885MAPT 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.